Indians from the Asian subcontinent are the second largest immigrant group in the US with 4.2 million of them having settled there, according to data from 2018. They.
Johns Hopkins Medicine
Johns Hopkins Medicine researchers have identified a protein – DMBT1S8 – that is elevated in patients who develop chronic inflammation of the nasal and sinus cavities with polyps, such as the ones seen in this artist’s rendition. DMBT1S8 may be a target for future therapies. Credit: Public domain image courtesy of Nucleus Medical Art Library
Johns Hopkins Medicine researchers have identified a protein – DMBT1S8 – as a target for potential therapies to treat inflammation in the nasal and sinus cavities.
Nasal and sinus inflammation – known medically as chronic rhinosinusitis – is one of the most common chronic illnesses in the United States, according to the U.S. Centers for Disease Control and Prevention. But for people with the most severe form of the condition, chronic rhinosinusitis with nasal polyps, it isn’t your average stuffy nose.
Entering the fight against COVID-19
As first-year medical students receive their white coats, four marshal their efforts to support the Johns Hopkins COVID-19 response in India By Marc Shapiro / Published June 9, 2021
First-year medical students received their first laboratory coats at the Johns Hopkins University School of Medicine White Coat Ceremony on Monday. The presentation and cloaking of the white coat confers a commitment to the values of being a physician: humanism, compassion, altruism, leadership, excellence, and devotion to the well-being of others.
Pictured above are (from left) Shrey Kapoor, Ashish Vankara, Pranjal Agrawal, and Divyaansh Raj, four students who received their white coats at the ceremony. They are also the co-chairs of the Johns Hopkins chapter of the South Asian Medical Students Association, through which they are aiding India s COVID-19 effort by filling in gaps identified by Johns Hopkins faculty and p
Minnesota cannabis firm expands in psychedelic medicines, sets new revenue target
Minnesota cannabis firm expands in psychedelic medicines, sets new revenue target Vireo Health is taking on a new name, Goodness Growth Holdings, as it branches out with a biosciences research subsidiary. June 9, 2021 10:53am Text size Copy shortlink:
Vireo Health International, a producer of cannabis products based in Minneapolis, renamed itself Goodness Growth Holdings and said Wednesday it will begin research in psychedelic medicine.
Shares in the company, which are traded on the Toronto Stock Exchange and over the counter in the U.S., rose 2% on the news.
The company led by Dr. Kyle Kingsley, a former Twin Cities emergency room doctor disillusioned that much of his work involved abuse of prescription drugs and alcohol is one of America s leading growers and retailers of cannabis products for medical